Financial Review: Haemonetics (NYSE:HAE) and Senestech (NASDAQ:SNES)

Haemonetics (NYSE:HAE) and Senestech (NASDAQ:SNES) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations and earnings.

Valuation and Earnings

This table compares Haemonetics and Senestech”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Haemonetics	$1.36 billion	2.41	$167.68 million	$3.42	20.51
Senestech	$1.86 million	5.73	-$6.18 million	($3.65)	-0.56

Haemonetics has higher revenue and earnings than Senestech. Senestech is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Haemonetics and Senestech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Haemonetics	12.67%	27.22%	9.52%
Senestech	-253.54%	-98.35%	-73.17%

Volatility & Risk

Haemonetics has a beta of 0.29, indicating that its share price is 71% less volatile than the S&P 500. Comparatively, Senestech has a beta of 0.19, indicating that its share price is 81% less volatile than the S&P 500.

Insider & Institutional Ownership

99.7% of Haemonetics shares are owned by institutional investors. Comparatively, 5.2% of Senestech shares are owned by institutional investors. 1.8% of Haemonetics shares are owned by insiders. Comparatively, 5.3% of Senestech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Haemonetics and Senestech, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Haemonetics	1	3	7	1	2.67
Senestech	1	1	0	1	2.33

Haemonetics presently has a consensus target price of $84.40, indicating a potential upside of 20.34%. Given Haemonetics’ stronger consensus rating and higher probable upside, research analysts clearly believe Haemonetics is more favorable than Senestech.

Summary

Haemonetics beats Senestech on 11 of the 13 factors compared between the two stocks.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

About Senestech

SenesTech, Inc. develops a technology for managing animal pest populations through fertility control. It offers ContraPest, a liquid bait that limits reproduction of male and female rats. The company was incorporated in 2004 and is headquartered in Phoenix, Arizona.